Compare Fidelity National Information Servcs Inc (FIS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Incyte Corporation — how do they compare? Fidelity National Information Servcs Inc trades at $41.71 (market cap $22.05B), while Incyte Corporation trades at $120.56 (market cap $24.54B). The key difference: Fidelity National Information Servcs Inc and Incyte Corporation are close in size by market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FIS | INCY | |
|---|---|---|
Market Cap | $22.05B | $24.54B |
Sector | Technology | Health |
52-Week High | $72.77 | $129.93 |
52-Week Low | $37.72 | $81.61 |
Enterprise Value | $42.56B | $20.04B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.51, down 0.61% today. The stock shows mixed signals with a bearish technical trend but strong fundamentals, including a low P/E of 6.57 and robust ROE of 22.33%. Recent Q2 2026 earnings beat expectations, driven by Banking Solutions growth, though full-year guidance was trimmed. Positive news includes global platform expansions in APAC and industry recognition for treasury software.
The outlook is cautiously optimistic. Attractive valuation and profitability metrics present an opportunity, but risks include execution challenges in Capital Markets and competitive pressures. Analyst consensus is strongly Buy with a $50.18 price target, suggesting significant upside potential from current levels if growth initiatives succeed.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
